Lv79
5000 积分 2024-01-09 加入
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
7个月前
已完结
Advances and prospects of biomarkers for immune checkpoint inhibitors
1年前
已完结
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
1年前
已完结
Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis
1年前
已完结
Unveiling the mechanisms and challenges of cancer drug resistance
1年前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
1年前
已完结
皖公网安备34019202002308
